Suppr超能文献

NG-硝基-L-精氨酸甲酯(L-NAME)对一氧化氮合成的抑制作用:需要生物活化为游离酸NG-硝基-L-精氨酸。

Inhibition of nitric oxide synthesis by NG-nitro-L-arginine methyl ester (L-NAME): requirement for bioactivation to the free acid, NG-nitro-L-arginine.

作者信息

Pfeiffer S, Leopold E, Schmidt K, Brunner F, Mayer B

机构信息

Institut für Pharmakologie und Toxikologie, Karl-Franzens-Universität Graz, Austria.

出版信息

Br J Pharmacol. 1996 Jul;118(6):1433-40. doi: 10.1111/j.1476-5381.1996.tb15557.x.

Abstract
  1. The L-arginine derivatives NG-nitro-L-arginine (L-NOARG) and NG-nitro-L-arginine methyl ester (L-NAME) have been widely used to inhibit constitutive NO synthase (NOS) in different biological systems. This work was carried out to investigate whether L-NAME is a direct inhibitor of NOS or requires preceding hydrolytic bioactivation to L-NOARG for inhibition of the enzyme. 2. A bolus of L-NAME and L-NOARG (0.25 micromol) increased coronary perfusion pressure of rat isolated hearts to the same extent (21 +/- 0.8 mmHg; n = 5), but the effect developed more rapidly following addition of L-NOARG than L-NAME (mean half-time: 0.7 vs 4.2 min). The time-dependent onset of the inhibitory effect of L-NAME was paralleled by the appearance of L-NOARG in the coronary effluent. 3. Freshly dissolved L-NAME was a 50 fold less potent inhibitor of purified brain NOS (mean IC50 = 70 microM) than L-NOARG (IC50 = 1.4 microM), but the apparent inhibitory potency of L-NAME approached that of L-NOARG upon prolonged incubation at neutral or alkaline pH. H.p.l.c. analyses revealed that NOS inhibition by L-NAME closely correlated with hydrolysis of the drug to L-NOARG. 4. Freshly dissolved L-NAME contained 2% of L-NOARG and was hydrolyzed with a half-life of 365 +/- 11.2 min in buffer (pH 7.4), 207 +/- 1.7 min in human plasma, and 29 +/- 2.2 min in whole blood (n = 3 in each case). When L-NAME was preincubated in plasma or buffer, inhibition of NOS was proportional to formation of L-NOARG, but in blood the inhibition was much less than expected from the rates of L-NAME hydrolysis. This was explained by accumulation of L-NOARG in blood cells. 5. These results suggest that L-NAME represents a prodrug lacking NOS inhibitory activity unless it is hydrolyzed to L-NOARG. Bioactivation of L-NAME proceeds at moderate rates in physiological buffers, but is markedly accelerated in tissues such as blood or vascular endothelium.
摘要
  1. L-精氨酸衍生物NG-硝基-L-精氨酸(L-NOARG)和NG-硝基-L-精氨酸甲酯(L-NAME)已被广泛用于在不同生物系统中抑制组成型一氧化氮合酶(NOS)。开展这项工作是为了研究L-NAME是一氧化氮合酶的直接抑制剂,还是需要先水解生物活化为L-NOARG才能抑制该酶。2. 静脉注射L-NAME和L-NOARG(0.25微摩尔)使大鼠离体心脏的冠状动脉灌注压升高到相同程度(21±0.8 mmHg;n = 5),但添加L-NOARG后效应出现得比L-NAME更快(平均半衰期:0.7对4.2分钟)。L-NAME抑制效应的时间依赖性出现与冠状动脉流出液中L-NOARG的出现平行。3. 新溶解的L-NAME对纯化脑NOS的抑制效力(平均IC50 = 70微摩尔)比L-NOARG(IC50 = 1.4微摩尔)低50倍,但在中性或碱性pH下长时间孵育后,L-NAME的表观抑制效力接近L-NOARG。高效液相色谱分析表明,L-NAME对NOS的抑制与药物水解为L-NOARG密切相关。4. 新溶解的L-NAME含有2%的L-NOARG,在缓冲液(pH 7.4)中的水解半衰期为365±11.2分钟,在人血浆中为207±1.7分钟,在全血中为29±2.2分钟(每种情况n = 3)。当L-NAME在血浆或缓冲液中预孵育时,对NOS的抑制与L-NOARG的形成成正比,但在血液中抑制作用远低于根据L-NAME水解速率预期的水平。这可以通过L-NOARG在血细胞中的积累来解释。5. 这些结果表明,L-NAME是一种前药,除非水解为L-NOARG,否则缺乏NOS抑制活性。L-NAME在生理缓冲液中的生物活化以中等速率进行,但在血液或血管内皮等组织中明显加速。

相似文献

引用本文的文献

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验